Neoadjuvant docetaxel, oxaliplatin, and S‑1 therapy for patients with large type 3 or type 4 gastric cancer: short‑term outcomes of a multicenter, phase II study (OGSG1902)
2024
A Phase II Trial of Trastuzumab Combined With Irinotecan in Patients With Advanced HER2‐positive Chemotherapy‐refractory Gastric Cancer (OGSG1203 HERBIS‐5): Final Results
Impact of subsequent chemotherapy after protocol treatment on overall survival in the RINDBeRG trial RINDBeRG試験における後治療の有効性に対する影響
Neoadjuvant chemoradiotherapy for clinical resectable type 4 and large type 3 gastric cancer patient (OGSG1205)
胃癌術後S-1補助化療患者に対する成分栄養剤のアドヒアランスと予後との関連（OGSG1108追加観察研究）
胃癌術後S-1補助化学療法患者に対する成分栄養剤の有用性に関する第Ⅱ相臨床試験(OGSG1108)の追加観察研究
Salvage-line of Capecitabine Plus Oxaliplatin Therapy (XELOX) for Patients With Inoperable/Advanced Gastric Cancer Resistant/Intolerant to Cisplatin (OGSG1403)
Phase I/II Study of Neoadjuvant Chemoradiotherapy Consisting of S‑1 and Cisplatin for Patients with Clinically Resectable Type 4 or Large Type 3 Gastric Cancer (OGSG1205)
Phase I study of neoadjuvant chemoradiotherapy with S‑1 for clinicallyresectable type 4 or large type 3 gastric cancer in elderly patients aged75 years and older (OGSG1303)
Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902)